Furmonertinib, AFATINIB, OSIMERTINIB, OSIMERTINIB, AFATINIB, AFATINIB
FURMO-006
Phase 3 small_molecule active
Quick answer
Furmonertinib, AFATINIB, OSIMERTINIB, OSIMERTINIB, AFATINIB, AFATINIB for Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations is a Phase 3 program (small_molecule) at ArriVent BioPharma with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ArriVent BioPharma
- Indication
- Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active